Package Leaflet: Information for the User
Glimepiride Aurovitas 2 mg Tablets EFG
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
-Keep this leaflet, as you may need to read it again.
-If you have any questions, ask your doctor or pharmacist.
-This medicine has been prescribed for you only. Do not give it to others even if they have the same symptoms as you, as it may harm them.
-If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. See section 4.
1.What Glimepiride Aurovitas is and what it is used for
2.What you need to know before you start taking Glimepiride Aurovitas
3.How to take Glimepiride Aurovitas
4.Possible side effects
5.Storage of Glimepiride Aurovitas
6.Contents of the pack and additional information
Glimepirida Aurovitas is a medication that lowers blood sugar levels, taken orally. This medication belongs to a group of medications that lower blood sugar levels called sulfonylureas. Glimepirida Aurovitas increases the amount of insulin released by your pancreas. Insulin lowers your blood sugar levels.
What is Glimepirida Aurovitas used for:
Glimepirida Aurovitas is used to treat a type of diabetes (type 2 diabetes mellitus) when diet, physical exercise, and weight reduction have not been able to control your blood sugar levels.
Do not take Glimepiride Aurovitas and talk to your doctor if:
Do not take this medicine if any of the above circumstances affect you. If you are unsure, consult your doctor or pharmacist before taking Glimepiride Aurovitas.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Glimepiride Aurovitas if::
If you are unsure whether anything mentioned above affects you, consult your doctor or pharmacist before taking Glimepiride Aurovitas.
It may occur that your red blood cell count decreases and you develop a rupture of red blood cells (hemolytic anemia) in patients who lack an enzyme called glucose-6-phosphate dehydrogenase.
The available information on the use of glimepiride in people under 18 years is limited. Therefore, its use is not recommended in these patients.
Important information about hypoglycemia (low blood sugar)
If you are taking glimepiride, you may have hypoglycemia (low blood sugar). See below for additional information about hypoglycemia, its symptoms, and treatment.
The following factors may increase the risk of you suffering hypoglycemia:
The symptoms of hypoglycemia include:
If your blood sugar levels continue to drop, you may have severe confusion (delirium), seizures, loss of self-control, shallow breathing, and a slow heart rate, and you may become unconscious. The clinical procedure for a severe drop in blood sugar is similar to a stroke.
Treatment of hypoglycemia:
In most cases, the symptoms of low blood sugar disappear quickly when you take something sweet, such as sugar cubes, sweet juices, or sweet tea.
Therefore, you should always carry something sweet (such as sugar cubes) with you. Please note that artificial sweeteners are not effective. Please consult your doctor or go to the hospital if, after taking sugar, you do not recover or if the symptoms recur.
Blood tests
Your blood sugar levels or urine must be regularly monitored. Your doctor may also ask for blood tests to check your red blood cell count and see how your liver is functioning.
Children and adolescents
Glimepiride Aurovitas is not recommended for use in children under 18 years.
Other medications and Glimepiride Aurovitas
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Your doctor may want to change your Glimepiride Aurovitas dose if you are taking other medications that can decrease or increase the effect of glimepiride on your blood sugar levels.
The following medications may increase the hypoglycemic effect of glimepiride. This may lead to a risk of hypoglycemia (low blood sugar):
The following medications may decrease the hypoglycemic effect of glimepiride. This may lead to a risk of hyperglycemia (high blood sugar):
The following medications may increase or decrease the hypoglycemic effect of glimepiride:
Glimepiride may also increase or decrease the effects of the following medications:
Colesevelam, a medication used to lower cholesterol, affects the absorption of glimepiride. To avoid this effect, it is recommended to take glimepiride at least 4 hours before colesevelam.
Taking Glimepiride Aurovitas with food, drinks, and alcohol
The consumption of alcohol may increase or decrease the hypoglycemic effect of glimepiride in an unpredictable manner.
Pregnancy, breastfeeding, and fertility
Pregnancy
Glimepiride Aurovitas should not be taken during pregnancy. If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before using this medication.
Breastfeeding
Glimepiride Aurovitas may pass into breast milk. It should not be used during breastfeeding.
Consult your doctor or pharmacist before taking any medication.
Driving and operating machines
Your ability to concentrate and react may be impaired due to the symptoms caused by hypoglycemia or hyperglycemia, such as difficulty seeing.This may be hazardous in situations where these skills are important (such as driving or operating machines). Therefore, consult your doctor if it is recommended to drive or operate machines.
Please consult your doctor if you can drive if:
Glimepiride Aurovitas contains lactose.Consult your doctor if you have been told that you have an intolerance to certain sugars before taking this medication.
Glimepiride Aurovitas contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially “sodium-free”.
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
How to take this medication
The tablet can be divided into equal doses.
How much to take
The dose depends on your needs, condition, and results of your blood sugar and urine analysis, and will be established by your doctor. Do not take more tablets than your doctor has told you.
If you take more Glimepiride Aurovitas than you should
If you have taken too much glimepiride or an additional dose, there is a risk of hypoglycemia (for signs of hypoglycemia see section 2 - "Warnings and precautions"), and therefore you should consume sufficient sugar immediately (e.g., sugar cubes, sweet juices, sweet tea) and inform your doctor immediately. When treating hypoglycemia due to accidental ingestion in children, the amount of sugar to be administered should be carefully controlled to avoid the possibility of producing a dangerous hyperglycemia. People in a coma should not take food or drinks.
Since hypoglycemia can last for a while, it is very important that the patient be closely monitored until there is no longer a risk. It may be necessary as a safety measure to be admitted to the hospital. Show the packaging or tablets that are left for your doctor to know what you have taken.
Severe cases of hypoglycemia accompanied by loss of consciousness and severe neurological failure are medical emergencies that require immediate medical treatment and hospitalization.You should ensure that there is always someone informed who can call a doctor in case of an emergency.
If you forgot to take Glimepiride Aurovitas
If you forget a dose, do not take a double dose to compensate for the missed doses.
If you interrupt the treatment with Glimepiride Aurovitas
If you interrupt or stop treatment, keep in mind that the desired effect of reducing blood sugar will not be achieved or that the disease will worsen again. Continue taking Glimepiride Aurovitas until your doctor tells you to stop.
If you have any other doubts about the use of this medication, consult your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Consult your doctor immediately if you experience any of the following symptoms:
Some patients have experienced the following side effects while taking Glimepiride Aurovitas:
Rare side effects(affect up to 1 in 1,000 people)
These changes usually disappear when treatment with Glimepiride Aurovitas is discontinued.
Very rare side effects(affect up to 1 in 10,000 people)
Frequency not known (cannot be estimated from available data):
Reporting of side effects:
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD.The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Do not use Glimepiride Aurovitas if you observe visible signs of deterioration.
Medications should not be disposed of through drains or in the trash. Dispose of packaging and medications you no longer need at the SIGRE collection point at the pharmacy.If in doubt, ask your pharmacist how to dispose of packaging and medications you no longer need. This will help protect the environment.
Composition of Glimepiride Aurovitas
Appearance of the product and contents of the package
Uncoated white to off-white tablets, oblong, with flat faces, scored on both faces, with “Y” and “32” engraved on one side of the score of one face and not engraved on the other.
The tablet can be divided into equal doses.
Blister pack: 15, 30, 50, 60, 90, and 120 tablets.
High-density polyethylene (PEAD) bottle: 500 tablets.
Only some packaging sizes may be commercially available.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder:
Aurovitas Spain, S.A.U.
Avda. de Burgos, 16-D
28036 Madrid
Tel: 91 630 86 45
Fax: 91 630 26 64
Responsible manufacturer:
APL Swift Services (Malta) Limited
HF26, Half Far Industrial Estate, Hal Far,
Birzebbuggia, BBG 3000
Malta
This medicine is authorized in the member states of the European Economic Area with the following names:
Spain:Glimepiride Aurovitas2 mg tablets EFG
Italy:GLIMEPIRIDEAUROBINDO
Netherlands:Glimepiride Aurobindo2 mgtabletten
Poland:Glimepiride Aurovitas
Portugal:Glimepiride Aurovitas
Czech Republic:Glimepirid Aurovitas
Last review date of this leaflet:May 2021
More detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/)
The average price of Glimepirida aurovitas 2 mg comprimidos efg in July, 2025 is around 10.18 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.